Medical talc for instillation in the case of malignant pleural effusion or pneumothorax

  • Granulometrically modified talc
  • Sterile
  • Asbestos-free
  • Endotoxin-free


  • Malignant pleural effusion
  • Pneumothorax

Recommended dose

  • 2 to 5 g for pleural effusion and
  • 2 g for pneumothorax.


STERITALC® is suitable for all indications for pleurodesis. It is insoluble and induces permanent pleurodesis. Talc pleurodesis is more effective and less painful than tetracyclines.


STERITALC® has been the standard of care for decades. Thousands of patients worldwide have been successfully treated with STERITALC®.

It is the only talc-based pleurodesis product with a well-documented and proven track record of safety and efficacy.

21 clinical studies from16 countries involving 2486 patients over a period of  25 years


“The most important clinical implication of our study is that largeparticle talc can safely be used for pleurodesis. Other talc preparations should not be used for this indication.”
Janssen et al.: Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369: 1535-1539

„Es gilt als gesichert, dass es beim französischen Luzenac-Talk (… STERITALC®, NOVATECH) zu keiner systemischen Talkumdissemination kommt.“
“It is accepted as certain that the French Luzenac talc (… STERITALC®, NOVATECH) does not result in a systemic talc dissemination.”
Schnyder / Tschopp: Behandlung des Pneumothorax mittels internistisch-thorakoskopischer Talkumpleurodese. Der Pneumologe 2010. 7: 357-363

A summary of selected papers on STERITALC® is available. Please contact us!


Meeting the particularly stringent requirements of the US Food and Drug Administration (FDA), STERITALC® is approved in the USA.

Excerpt from the US Prescribing Information for STERITALC®:

There are published reports of two large, prospective trials conducted to evaluate the safety of STERITALC® administered intrapleurally. One trial evaluated 558 patients treated with STERITALC® 4 g by poudrage for MPE. The second trial evaluated 418 patients with recurrent primary spontaneous pneumothorax treated with STERITALC® 2 g by poudrage. No cases of ARDS or talc-related lung injury were reported.


Ordering Information

REFDescriptionQuantity of medical talcitems per box
16903STERITALC® F2 Vial, 50 ml2 g4
16913STERITALC® F4 Vial, 50 ml4 g4

STERITALC® PF3 (Poudrage Kit)
Vial 10 ml, with balloon and cannula,
L: 420 mm, OD: 3.0 mm

3 g2 kits
16983Supplement for 16863: Vial, 10 ml3 g4


International availability of STERITALC®